相关实验视频
Updated: Jan 25, 2026

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.8K
工程无标记剂的生菜基因组,以表达功能性葡萄糖样-1受体激活剂exenatide和lixisenatide
1Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Plant biotechnology journal
|January 24, 2026
概括
这项研究使用转基因开发了可负担得起的,口服的葡萄糖样-1受体激动剂 (GLP-1RAs). 这些基于植物的生物制品为昂贵的注射糖尿病药物提供了有希望的替代品.
科学领域:
- 植物生物技术 植物生物技术
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病影响全球超过5亿人,死亡率高.
- 目前的葡萄糖类-1受体激动剂 (GLP-1RAs) 是昂贵的,需要注射,并且有诸如高剂量和胃肠道问题等局限性.
- 人们需要负担得起,对患者友好的糖尿病治疗方法.
研究的目的:
- 开发一种可负担得起的,可口服输送的GLP-1RAs形式,使用一种植物性表达系统.
- 为了提高患者的遵从性,并降低糖尿病管理的治疗成本.
主要方法:
- 优化了Codon的Exenatide和Lixisenatide与霍乱毒素B亚单元 (CTB) 融合,并表达为生菜的叶绿体.
- 转基因菜系被证实具有转基因整合,同质体和使用PCR和南方斑点的标记基因去除能力.
- 通过组装和GLP-1受体结合试验的GM1 ELISA来评估功能.
主要成果:
- 功能性CTB-Exenatide和CTB-Lixisenatide在没有标记物的生菜中得到了成功的表达.
- 表达水平达到1.94 mg/g和3.64 mg/g的植物粉末,在随后的几代人中增加.
- 融合蛋白显示出正确的组装和显著的GLP-1受体结合,表明生物活性.
结论:
- 这项研究在可食用,无标记物植物系统中首次表达了功能GLP-1RAs.
- 与合成替代品相比,这种方法显著降低了所需剂量,为负担得起的口服生物制剂铺平了道路.
- 这一创新有潜力推进临床研究,改善糖尿病治疗的可用性.
相关概念视频
Glucagon-like Receptor Agonists
875
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
875
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
15.5K
The present-day mitochondrial and chloroplast genomes have retained some of the characteristics of their ancestral prokaryotes and also have acquired new attributes during their evolution within eukaryotic cells. Like prokaryotic genomes, mitochondrial and chloroplast genomes neither bind with histone-like proteins nor show complex packaging into chromosome-like structures, as observed in eukaryotes. Unlike mitotic cell divisions observed in eukaryotic cells, mitochondria and chloroplasts...
15.5K
Export of Mitochondrial and Chloroplast Genes
4.1K
A eukaryotic cell can have up to three different types of genetic systems: nuclear, mitochondrial, and chloroplast. During evolution, organelles have exported many genes to the nucleus; this transfer is still ongoing in some plant species. Approximately 18% of the Arabidopsis thaliana nuclear genome is thought to be derived from the chloroplast’s cyanobacterial ancestor, and around 75% of the yeast genome derived from the mitochondria’s bacterial ancestor. This export has occurred...
4.1K
Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Anatomy of Chloroplasts
119.2K
Green algae and plants, including green stems and unripe fruit, harbor chloroplasts—the vital organelles where photosynthesis takes place. In plants, the highest density of chloroplasts is found in the mesophyll cells of leaves.
119.2K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
926
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
926

